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Univariate sensitivity analysis was done. RESULTS: Over the time horizon 
evaluated, prophylactic treatment avoids 681 cases of bleeding and 246 of joint 
damage. Total expected costs with prophylactic treatment were US$3.86M 
compared to on demand treatment US$2.09M. The incremental cost 
effectiveness ratio (ICER) for prophylactic treatment was US$2592/avoided 
bleeding and US$7172/avoided joint damage (cost-effectiveness threshold: 1 
Colombian GDP per capita = US$7235). Sensitivity analyses showed the 
robustness of the model. CONCLUSIONS: Prophylactic treatment of severe 
hemophilia B, with recombinant factor IX would be a highly cost-effective 
intervention from the social perspective.  
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OBJECTIVES: Chronic migraine produces significant societal costs and reductions 
in quality of life. OnabotulinumtoxinA is licensed in Canada for the prophylaxis 
of headaches in adults with chronic migraine. We developed a model to estimate 
the cost-effectiveness of onabotulinumtoxinA for patients with chronic migraine 
who are intolerant or refractory to two or more oral prophylaxis agents. 
METHODS: A state transition model with a three-year time horizon was 
developed to estimate the incremental impact of onabotulinumtoxinA relative to 
placebo in units of quality adjusted life years (QALYS) for adults with chronic 
migraine in Canada. Each treatment cohort was divided into health states 
defined by the number of headache days experienced per month. A societal 
perspective was taken, including cost of treatment, acute health care resource 
use, absenteeism, and presenteeism. Pooled data from the subgroup of patients 
who had previously tried two or more prophylactics in the Phase III clinical trial 
program were used to estimate the baseline health state distributions and 
transition probabilities. Quality of life and health care resource utilization were 
estimated from a large international observational study of migraine patients. 
RESULTS: Treatment with onabotulinumtoxinA produced an incremental benefit 
of 0.151 QALYs over 3 years at an incremental cost of $974 compared to placebo, 
thus resulting in an Incremental Cost Effectiveness Ratio (ICER) of $6,450/QALY. 
Results were most sensitive to hourly wage, mean lost work hours, and mean 
number of hospitalizations in the three highest headache days per month health 
states. OnabotulinumtoxinA remains cost-effective when excluding lost 
productivity costs, with an ICER of $24,504/QALY. CONCLUSIONS: In this study, 
onabotulinumtoxinA was shown to be a cost-effective treatment option and may 
be considered good value for money from a Canadian societal perspective for the 
prophylaxis of headaches in adults with chronic migraine who fail or are 
intolerant to other treatment options.  
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OBJECTIVES: Fibromyalgia is a disorder often characterized by chronic 
musculoskeletal pain over multiple regions of the body not explained by 
anatomical injury. Pregabalin is the only approved medication for fibromyalgia 
in Taiwan. This study aims to estimate the cost-effectiveness of pregabalin for 
treatment of severe fibromyalgia in Taiwan. METHODS: A decision-analytic 
model was constructed for projecting the effects and costs of pharmaceutical 
treatment of fibromyalgia sufferers in Taiwan. Treatment comparators and 
utilization patterns were provided through local physician questionnaires and a 
national key opinion leader advisory board (rheumatologist, pain specialists and 
neurologist). Costs were collected from local published data. Response (30% 
improvement over baseline in pain score and patient global impression) and 
non-response of a single patient were modeled to pregabalin 300mg or 450mg 
versus placebo and alternative medications used in practice as suggested by the 
advisory board (amitriptyline 25mg, duloxetine 60/120mg, tramadol 200mg, or 
gabapentin 1800mg) for 12 weeks, followed by a three-year Markov model 
depicting maintained response, lost response, or stopped treatment. Transition 
probabilities were retrieved from published randomized trials. Effectiveness was 
quality-adjusted life years (QALYs). Costs and QALYs were annually discounted 
at 3%. Annual costs were reported in 2013 US$. RESULTS: The base case patient 
was a 42 year old woman. Compared pregabalin 300mg and 450mg with placebo, 
the incremental cost-effectiveness ratios (ICERs) were $33,369/QALY and 
$49,040/QALY. The ICERs for pregabalin 300mg versus duloxetine 60mg/120mg, 
tramadol, or gabapentin were $33,009/QALY, $3,377/QALY, $189,956/QALY, and 
$36,318/QALY, respectively. The ICERs for pregabalin 450mg versus duloxetine 
60mg, duloxetine 120mg, tramadol, or gabapentin were $63,970/QALY, 
$39,697/QALY, $237,612/QALY, and $66,755/QALY, respectively. Both pregabalin 
300mg and 450mg had higher cost and lower QALYs than amitriptyline. The 
results are robust under probabilistic sensitivity analysis. CONCLUSIONS: 
Depending on a budgetary authority’s willingness to pay, pregabalin may be 
cost-effective against placebo and alternative treatments.  
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OBJECTIVES: Urinary incontinence (UI) secondary to a neurogenic pathology, 
including spinal cord injury (SCI) and Multiple Sclerosis (MS), is termed 
neurogenic detrusor overactivity (NDO). Patients with NDO experience a 
decrease in quality of life (QoL) and are at risk for upper urinary tract damage. 
We sought to investigate the clinical and economic impact of 
onabotulinumtoxinA treatment for UI due to NDO from the US payer perspective. 
METHODS: We developed a Markov state transition model to estimate outcomes 
and costs for anticholinergic refractory NDO patients who received 
onabotulinumtoxinA or best supportive care (BSC). Non-responding patients 
(<50% reduction in UI episodes at 6 weeks) were eligible to receive invasive 
procedures (i.e. augmentation cystoplasty or sacral neuromodulation). Patients 
could transition through six health states defined by response to initial 
treatment, invasive procedures, and death. Time in each health state was 
adjusted for patient QoL and summed to estimate quality-adjusted life years 
(QALY). We included direct medical costs related to medications and invasive 
treatments, physician visits, and catheterization. Outcomes and costs were 
compared using the incremental cost-effectiveness ratio. The time horizon of the 
model was 3 years and results were discounted at 3%. RESULTS: 
OnabotulinumtoxinA increased QALYs by 0.059 and costs by $1,466 compared to 
best supportive care, yielding an estimated ICER of $24,720/QALY. 
OnabotulinumtoxinA also decreased mean incontinence episodes per person-
year by 400, resulting in a cost of $4 per incontinence episode avoided. Model 
results were most sensitive to the probability of treatment response. The 
probabilistic sensitivity analysis indicated that at a willingness to pay of 
$50,000/QALY, onabotulinumtoxinA has a 97% probability of being cost-effective. 
In subgroup analyses of each etiology, onabotulinumtoxinA yielded an ICER of 
$32,268/QALY in MS and $2,182 in SCI. CONCLUSIONS: OnabotulinumtoxinA 
appears to be a cost-effective intervention for UI due to NDO when compared to 
best supportive care.  
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OBJECTIVES: Examine the number of hospitalizations, emergency room  
(ER) visits, fractures, and falls among patients diagnosed with Parkinson Disease 
(PD) initiating therapy with either Selegiline (SEL) or Rasagiline (RAS). METHODS: 
This study utilized data from the Truvan Health Analytics MarketScan Claims 
and Encounters Database from 1/1/2006 through 3/31/2011. Eligible patients  
filled a prescription for SEL or RAS, with first such date identified as index date, 
were diagnosed with PD (ICD-9-CM 332 or 332.0) in the 2 years post the index 
date (i.e., the post-period), and were continuously insured from 6 months prior 
(i.e., the pre-period) through the end of the post-period. Logistic regressions  
were utilized to estimate adjusted odds ratios of hospitalizations and ER visits 
(both total and PD-related) as well as odds of fractures and falls,  
while controlling for socio-demographic and clinical characteristics. The apriori 
specified level of significance was 5%. RESULTS: There were 3,864 individuals  
in the analyses (1,085 SEL; 2,779 RAS). On average, RAS patients were slightly 
younger (56.3 v 56.8 years; P=0.0320), had a significantly higher copayment 
associated with initial prescription ($44.72 v $21.36; P<0.0001) and  
were significantly more likely to have a comorbid diagnosis of high cholesterol 
(18.10% v 14.01%; P=0.0023). After controlling for patient characteristics, general 
health, disability status, comorbid diagnoses, and index prescription 
characteristics, RAS was associated with significantly lower likelihood of  
all-cause hospitalizations in the post-period (OR=0.821; 95% CI= 0.682 – 0.988), 
all-cause ER visits (OR=0.791; CI =0.677 – 0.926), PD-related ER visits (OR=0.793; 
CI=0.643 – 0.979), and falls (OR=0.552; CI=0.335 – 0.909) compared to  
patients initiating with SEL. There was not a significant difference between the 
cohorts in the odds of fracture or the odds of a PD-related hospitalization. 
CONCLUSIONS: Among patients with PD, initiation with RAS compared to SEL is 
associated with significantly fewer all-cause hospitalizations and ER visits and 
fewer falls.  
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OBJECTIVES: Patient perceptions regarding disease modifying therapies (DMT) in 
multiple sclerosis (MS) are limited to a few studies. Although DMT use has been 
shown to be beneficial in terms of preventing relapses and disability progression, 
many MS patients do not initiate therapy for unclear reasons. The objectives 
were to quantify and evaluate perceptions of MS patients not currently being 
treated with DMTs towards MS as a disease state and DMT initiation, in  
a regional health plan using the Multiple Sclerosis Medication Questionnaire 
